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Abstract Sprouty proteins are evolutionarily conserved mod-
ulators of MAPK/ERK pathway. Through interacting with an
increasing number of effectors, mediators, and regulators with
ultimate influence on multiple targets within or beyond ERK,
Sprouty orchestrates a complex, multilayered regulatory system
and mediates a crosstalk among different signaling pathways
for a coordinated cellular response. As such, Sprouty has been
implicated in various developmental and physiological process-
es. Evidence shows that ERK is aberrantly activated in malig-
nant conditions. Accordingly, Sprouty deregulation has been
reported in different cancer types and shown to impact cancer
development, progression, and metastasis. In this article, we
have tried to provide an overview of the current knowledge
about the Sprouty physiology and its regulatory functions in
health, as well as an updated review of the Sprouty status in
cancer. Putative implications of Sprouty in cancer biology, their
clinical relevance, and their proposed applications are also
revisited. As a developing story, however, role of Sprouty in
cancer remains to be further elucidated.
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1 Introduction
Mitogen-activated protein kinase (MAPK) signaling path-
ways are among the most widespread regulatory mechanisms
of the eukaryotic cell biology. The first mammalian MAPK
pathway to be identified and entirely mapped is extracellular
signal-regulated kinase or MAPK/ERK (hereafter ERK).
ERK orchestrates a signal transduction from cell membrane
molecules to the transcriptional machinery to promote cell
growth, differentiation, and survival. As with other MAPKs,
ERK represents a three-tiered kinase cascade composed of
the sequentially-acting kinases. ERK is activated by a wide
range of extracellular signals including growth factors, cyto-
kines, hormones, and neurotransmitters. Signal transduction
is initiated when a ligand binds its transmembrane receptor
tyrosine kinase (RTK) and thereby activates Ras, a small G
protein anchored to the plasma membrane. Ras subsequently
recruits from the cytosol to the cell membrane and activates
Raf serine/threonine-specific kinases of MAPK-kinase kinase
(MAP3K) family. Through serine/threonine phosphorylation,
Raf activates a family of dual specificity kinases known as
MAPK kinases (MAP2K) or MAPK/ERK kinases (MEKs).
By concomitant tyrosine and threonine phosphorylation,
MEKs activate MAPK (Erk). Phosphorylated Erk eventually
induces gene expression by direct and indirect targeting of
transcription factors. To setup a biologically coordinated in-
frastructure for physiologically appropriate outcomes, ERK
and its core modules are under tight, multilayered control of
positive and negative regulators, including the Sprouty pro-
tein family.
Sprouty was discovered by Hacohen et al. who initially
described it as a common antagonist of fibroblast growth
factor (FGF) and epidermal growth factor (EGF) signaling
pathways in Drosophila [1, 2]. In a search of the Expressed
Sequence Tag (EST) database, they identified three human
homologs of the fly gene designated hSpry1-3 [1]. The fourth
mammalian homolog, hSpry4, was later discovered in mice
[3] and humans [4]. Emerging evidence later showed that
Sprouty specifically inhibits activation of ERK in response
to a wide range of trophic factors, including FGF [5, 6],
platelet-derived growth factor (PDGF) [5], vascular endothe-
lial growth factor (VEGF) [6], nerve growth factor (NGF) [7],
brain-derived neurotrophic factor (BDNF) [8], and glial cell
line-derived neurotrophic factor (GDNF) [9]. The biological
functions of the Sprouty proteins have been attributed to its
conserved motifs. These mainly include the N-terminal ca-
nonical Casitas B-lineage lymphoma (c-Cbl) binding domain
(CBD) containing a key tyrosine residue; the serine-rich motif
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(SRM); and the C-terminal cysteine-rich domain (CRD) also
known as the Sprouty (or translocation) domain. Among the
Sprouty isoforms, Spry2 exhibits the highest evolutionary
conservation, with the human Spry2 showing 97, 85, and
51 % sequence homology, in the CRD domain, to the mouse,
chick, and Drosophila protein, respectively [10]. Although
Spry2 appears to be ubiquitously expressed in embryonic
and adult tissues, the expression of other isoforms shows
organ/tissue specificity [4, 10, 11].
The Sprouty proteins are currently recognized as key reg-
ulators of ERK signaling that act on different levels of the
pathway. Furthermore, they are part of a tightly-orchestrated
regulatory mechanism where interactions with a variety of
players lay the basis for a crosstalk between ERK and partner
cascades. Nevertheless, aberrant activation of ERK and de-
regulation of Sprouty occurs in a variety of pathological
conditions, including malignant transformation. In this article,
complex functions of the Sprouty family under physiological
conditions are revisited, altered expression of Sprouty in dif-
ferent cancer types and its impact on cancer development,
progression, and metastasis studied by different investigators
are reviewed, and clinical application of the deregulated
Sprouty as a biological marker and/or a focus of targeted
strategies is discussed.
2 Sprouty: a versatile modulator with complex
functionality
Since discovery of Sprouty in 1998 [1], an expanding body of
evidence has continued to support its crucial role in regulation
of various physiological processes. Initial studies by
Minowada et al. [10] and Tefft et al. [12] revealed that this
protein family and its regulatory relationship with FGF-
induced signaling are evolutionarily conserved. Through
comparative genomic analysis, the linkage between the hu-
man Sprouty and FGF genes was later reported [13]. Sprouty
regulates tubular morphogenesis as a fundamental process in
organogenesis and angiogenesis where FGF signaling is par-
ticularly involved [14–16]. Apart from its crucial role in
embryogenesis, Sprouty has been implicated in regulation of
physiological events in adult organs. Table 1 summarizes a
number of studies in which implication of Sprouty in devel-
opmental and physiological events has been documented.
At cellular level, Sprouty modulates key processes includ-
ing proliferation, differentiation, motility, and survival
through regulation of ERK and parallel pathways, as well as
interaction with a number of effectors and regulators. As listed
in Table 2, various regulatory effects of the Sprouty proteins in
normal and neoplastic cells have been documented in litera-
ture. The Sprouty-mediated modulation, however, occurs in a
cell- and context-dependent manner where a number of facts
and factors, as described below, are involved in the determi-
nation of the eventual response.
2.1 Cell and context dependency
It is evident that cellular behavior in response to the growth
factor stimulation and Sprouty-mediated regulation varies
from cell to cell. For example, while Spry2 inhibits the differ-
entiation of PC12 pheochromocytoma cells in response to
FGF [5, 7], it promotes FGF-induced differentiation of
C2C12 myoblasts [48]. Depending on the cellular context
and innate physiological characteristics, different components
of the RTK signalosome are activated by different ligands
[73]. Moreover, strength and duration of the signal transduc-
tion are among critical determinants of cell fate in response to
activation and regulation of the RTK signaling [74]. In
NIH3T3 fibroblasts and PC12 cells, for example, whereas
transient activation of ERK during mid-G1 phase leads to cell
cycle progression and hence proliferation in the former,
sustained ERK activity induces cell-cycle withdrawal and
neuronal differentiation in the latter [75]. Accordingly,
Sprouty was shown to inhibit proliferation of NIH3T3 cells
and differentiation of PC12 cells in response to growth factor
stimulation [5]. It will be discussed in the following sections
that how Sprouty modulates the RTK signaling depending on
the intersection point where it interferes as well as on its
interplay with other interacting molecules.
2.2 Growth factor dependency and pathway sensitivity
Depending on the RTK activated and the downstream path-
way(s) affected, Sprouty differentially modulates growth fac-
tor actions and thereby elicits divergent responses. Hence,
Sprouty isoforms are able to selectively uncouple growth
factor-induced signal transductions. In a study by
Impagnatiello et al. [6] indicating an anti-proliferative effects
of the overexpressed Spry1 and Spry2 on endothelial cells in
the presence of FGF, VEGF, and EGF, while FGF- and
VEGF-induced activation of ERK were repressed by Sprouty,
EGF-activated ERK was left unaffected. It was revealed in a
study by Sasaki et al. [60] that the expression of Spry2 and
Spry4 in HEK293 cells inhibited FGF-induced ERK signaling
but did not affect EGF or PDBu activation of ERK. Converse-
ly, the expression of dominant negative mutants of Spry2 and
Spry4 enhanced and prolonged FGF, but not EGF, activation
of ERK. They later found that Spry4 suppresses VEGF-
induced, Ras-independent activation of Raf1 but does not
affect the Ras-dependent cascade induced by EGF [76]. Fur-
thermore, evidence supports a positive feedback loopwhereby
EGF stimulation of ERK signaling is potentiated and
sustained by Sprouty. This paradoxical effect was initially
investigated by Wong et al. [7] in PC12 cells employed as a
proliferation/differentiation responsivemodel. It is known that
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FGF and NGF induce differentiation of PC12 cells into a
neuron-like phenotype via sustained activation of ERK,
whereas EGF stimulation transiently activates ERK and thus
promotes cell proliferation [74, 77]. Wong et al. reported that
Spry1 and Spry2 inhibited differentiation of PC12 cells in-
duced by FGF-activated ERK, yet they augmented ERK ac-
tivity in response to EGF and hence promoted differentiation
of PC12 cells [7]. This effect represents an intriguing role of
Sprouty in protecting EGF receptor (EGFR), which will be
discussed later. UsingNIH3T3 and PC12 cells transfected with
Spry1 or Spry2, Gross et al. [5] observed that Sprouty restrict-
ed cell proliferation and growth factor-induced differentiation,
but did not promote apoptosis. The investigators found that
Spry1 and Spry2 impeded FGF or PDGF stimulation of ERK,
but did not affect phosphatidylinositol 3-kinase (PI3K)/AKT
pathway through which many RTK-mediated survival signals
are relayed. In another study, De Alvaro et al. indicated that
FGF stimulation of C2C12 myoblasts induces proliferation
and a differentiation-defective phenotype associated with
sustained activation of ERK and lack of activation of AKT.
Overexpressed Spry2, however, conferred myogenic differen-
tiation properties that were accompanied by repression of ERK
and activation of AKT [48].
2.3 Transcriptional regulation of the Sprouty expression
ERK pathway is known to generally upregulate Sprouty [78].
However, inducibility of the Sprouty isoforms in response to
the growth factor stimulation may vary in a cell type- and
context-dependent manner. In an initial study by Ozaki et al.,
Table 1 Sprouty implication in
developmental and physiological
processes reported by some
investigators
dSpry Drosophila Sprouty; hSpry
human Sprouty; mSpry mouse
Sprouty; xSpry Xenopus Sprouty;
zSpry zebra fish Sprouty
Investigators Sprouty isoform Developmental/Adult physiological event
Hacohen et al. [1] dSpry Tracheal development
Kramer et al. [2] dSpry Eye development
Minowada et al. [10] mSpry2 and 4 Limb development
Tefft et al. [12] mSpry2 Lung development
Furthauer et al. [17] zSpry4 Midbrain development
Zhang et al. [18] mSpry1, 2 and 4 Craniofacial and trunk development
Gross et al. [19] mSpry1 Kidney development
Chi et al. [20] hSpry2 Ureteric branching
Lo et al. [21] mSpry1 and 2 Breast development in puberty and pregnancy
Anteby et al. [22] hSpry1, 2, and 3 Placental villi sprouting
Haimov-Kochman et al. [23] hSpry2 Follicle maturation and corpus luteum formation
Lin et al. [24] mSpry2 Patterning of midbrain and anterior hindbrain
Shim et al. [25] mSpry2 Inner ear development
Basson et al. [26] mSpry1 Ureteric branching
Boros et al. [27] mSpry1 and 2 Ocular lens development
Chi et al. [28] mSpry2 Male sex organogenesis
Natanson-Yaron et al. [29] hSpry2 Placental villi sprouting
Price et al. [30] hSpry4 Kidney development
Gross et al. [8] mSpry2 Neuronal differentiation
Shaw et al. [31] mSpry2 Lung development
Laziz et al. [32] hSpry1, 2 and 4 Muscle regeneration
Hamel et al. [33] hSpry2 Oocyte developmental competence
Klein et al. [34] mSpry4 (+ mSpry1 or 2) Growth and development of rodent incisors
Jaggi et al. [35] mSpry4 Pancreas development
Wang et al. [36] xSpry1 Gastrulation
Pan et al. [37] mSpry2 Lens and lacrimal gland development
Purcell et al. [38] mSpry1 and 2 Temporomandibular Joint development
Sieglitz et al. [39] dSpry Neuronal and glial differentiation
Kuracha et al. [40] mSpry1 and 2 Eyelid closure
Velasco et al. [41] hSpry2 Endometrial gland developing and branching
Sigurdsson et al. [42] hSpry2 Breast morphogenesis
Ching et al. [43] mSpry1 and 2 External genitalia development
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the expression of the Sprouty genes, including Spry1, was
shown to be positively regulated by ERK [78]. Parallel studies
consistently reported that the expression of Spry2 and Spry4
was rapidly induced by growth factors in fibroblasts [5],
endothelial cells [6], and HEK293 cells [60], yet concomitant
downregulation of Spry1 was observed [5, 6]. Moreover, Kral
et al. [79] demonstrated that neither growth factor stimulation
nor Ras activation increased the Spry1 protein levels in WI38
normal human lung fibroblasts. Since Spry1 in their cell cycle
analysis with WI38 cells was constantly expressed, they con-
cluded that mitogenic signaling is not sufficient to modulate
the Spry1 expression, and that Spry1, as appeared in earlier
studies [19, 80, 81], is more likely modulated by differentia-
tion processes. In agreement, partner pathways and mecha-
nisms, too, have been shown to play a role in modulating
transcriptional expression of the Sprouty proteins. Choi et al.
[82] indicated that Spry1 is the only Sprouty isoform induced
by T cell receptor (TCR) stimulation in murine CD4+ T cells
and that ensuing expression of Spry1 with dual output impacts
TCR signaling depending on their differentiation state. In
contrast, Frank et al. observed in mouse splenic B cells that
combined activation of CD40 and B cell receptor (BCR),
known as a stimulator of B-cell proliferation and survival,
induces Spry2, but not Spry1, through an ERK-dependent
negative feedback loop which attenuates activation of ERK,
thereby implicating Spry2 in regulating antigen-induced ex-
pansion of mature B cells [67]. Ding et al. reported that
transforming growth factor-beta1 (TGFβ1) signaling
downregulates Spry2 protein in Swiss 3 T3 cells in a
MAPK-independent manner with possible involvement of
Smad pathway [53]. Later, they also implicated tumor necro-
sis factor-alpha (TNF-α) signaling in the Spry2 downregula-
tion via p38 MAPK led to apoptosis of Swiss 3 T3 fibroblasts
and MLE15 lung epithelial cells [54]. Different growth factor
isoformsmay also variably stimulate the RTK induction of the
Sprouty expression. Jiang et al. observed in granulosa cells
that while FGF1, FGF4, and FGF8 enhanced the expression of
Spry2 and Spry4, and FGF8 additionally increased the abun-
dance of Spry1messenger RNA (mRNA), FGF10 and FGF18
failed to induce the Sprouty expression [83, 84]. Moreover,
the presence of GC-rich regions in Spry1 [19], Spry2 [85], and
Spry4 [11] promoters suggests spatiotemporal regulation of
the Sprouty expression by tissue-specific transcription factors.
Accordingly, the transcription factorsWilms tumor suppressor
1 (WT1) [19], cAMP response element-binding protein
(CREB) and specificity protein 1 (SP1) [8], and peroxisome
proliferator-activated receptor gamma (PPARγ) [56] have
been implicated in normal development of kidney and central
nervous system, as well as in the inhibition of lung tumori-
genesis via activating Spry1, Spry2, and Spry4 promoters,
respectively. Also, Sabatel et al. identified Spry1 as a target
of the angiostatic agent 16K prolactin which was shown to
induce NF-kappaB-dependent upregulation of Spry1 in
primary and human endothelial cells. They showed that Spry1
silencing protects endothelial cells from apoptosis and induces
endothelial cell adhesion, migration, and tube formation and
argued that Spry1 acts as an endogenous inhibitor of angio-
genesis [86].
2.4 Modulation of the Sprouty stability by post-translational
mechanisms
Apart from transcriptional regulation of the protein expres-
sion, intracellular level of Sprouty is post-translationally
controlled, as well. Polyubiquitylation and proteasomal
degradation of active Sprouty mediated by the E3 ubiquitin
ligase c-Cbl is a tyrosine phosphorylation-dependent pro-
cess that temporally limits the Sprouty intervention [87,
88]. Mason et al. showed that although Spry2/c-Cbl com-
plex formation is dispensable for the inhibitory effect of
Spry2 on the FGF-activated ERK, it mediates degradation
of Spry2 in response to FGF. Thus, Spry2 accumulates to
higher levels and inhibits FGF-induced signaling more
efficiently in c-Cbl-null mouse embryonic fibroblasts
(MEFs) than in control MEFs [89, 90]. Reporting bimodal
expression of Spry2 along with sustained elevation of
Spry4 during cell cycle progression, Mayer et al. [91]
indicated that second phase in the expression profile of
Spry2 as transient attenuation of the protein expression
during late G1 is solely dependent on cell cycle-specific
ubiquitination by c-Cbl. DaSilva et al. [92] showed that
serine phosphorylation on Ser112 and Ser121 by MAPK-
interacting kinase 1 (Mnk1) provides Spry2 with balanced
phosphorylation of Tyr55 that leads to the protein stabili-
zation. As such, mutation of theses serine residues or
inhibition of Mnk1 augmented RTK-mediated phosphory-
lation of Tyr55, thereby enhancing c-Cbl-mediated degra-
dation of the protein. Edwin et al. [93] reported that the
HECT domain-containing E3 ubiquitin ligase Nedd4 binds
and polyubiquitinates Spry2 to regulates its cellular con-
tent along with its ability to modulate RTK signaling. They
found that Nedd4 requires Mnk2-dependent phosphoryla-
tion of Ser112/Ser121 for its interaction with Spry2. An-
other E3 ubiquitin ligase, Seven in Absentia homolog 2
(Siah2), has also been implicated in post-translational reg-
ulation of the Sprouty content. Nadeau et al. [94] indicated
that coexpression of Siah2 resulted in proteasomal degra-
dation of Spry1, Spry2, and, to a lesser extent, Spry4 in a
tyrosine phosphorylation-independent manner. As with c-
Cbl, it was shown that RING finger domain of Siah2 binds
the N-terminal domain of Spry2 to mediate their interac-
tion. Consistently, it was later reported that a dominant-
negative Siah2 RING mutant primarily increased the
Sprouty content and activity [95]. Furthermore, it was
demonstrated in a study by Ding et al. on Swiss 3 T3 cells
that TGFβ1 not only downregulates the expression of
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Spry2, but also induces the protein degradation via a
lysosome-dependent pathway [53]. They concluded that
downregulation of Spry2 by TGFβ1 at transcriptional
and post-translational levels lays a basis for crosstalk be-
tween TGFβ1 signaling and EGF, as well as FGF-induced
ERK in mesenchymal cells. Haigal et al. showed that
hypoxia increased the Spry4 expression in several cell
types through HIF-dependent transcription as well as in-
creased mRNA stability [96]. Furthermore, Anderson et al.
[97] demonstrated that prolyl hydroxylation of Spry2 by
prolyl hydroxylase domain proteins (PHDs) during
normoxia targets it for recognition and ubiquitination by
von Hippel-Lindau (pVHL)-associated E3 ubiquitin ligase.
Transcriptional and post-translational regulation of the
Sprouty cellular content is illustrated in Fig. 1.
2.5 Regulation of the Sprouty activity
Sprouty trafficking to and from the plasma membrane regu-
lates subcellular localization of Sprouty and hence keeps the
protein functionality under spatiotemporal control. In
unstimulated cells, Sprouty is distributed throughout the cy-
tosol, with hSpry2 being colocalized with microtubules, as
well. Upon growth factor activation, Sprouty translocates to
the plasma membrane, notably ruffles, where it becomes
activated in association with phosphatidylinositol 4,5-
bisphosphate (PIP2) and the caveolin-1 (Cav-1) [6, 98–100].
Lim et al. [100] demonstrated that Sprouty binds PIP2 through
its CRD domain and that this phenomenon is an essential
process for regulation of ERK signaling. As the major struc-
tural protein of caveolae (specialized plasma membrane
Fig. 1 Representative regulators of the Sprouty cellular content at tran-
scriptional and post-translational level irrespective of the Sprouty isoform
and cell type. MAPK/ERK is the main pathway to upregulate Sprouty.
Transcription factorsWT1 and PPARγ andWnt/β-catenin signaling path-
way have also been shown to upregulate Sprouty. miR-21 is a cancer-
associated microRNA that targets and negatively regulates the Sprouty
genes. TGFβ1 not only downregulates the expression of Sprouty, but also
induces the protein degradation via a lysosome-dependent pathway. E3
ubiquitin ligases c-Cbl, Siah2, NEDD4, and pVHL induce degradation of
Sprouty to regulate its cellular content. PP2A competes with c-Cbl for
binding to Sprouty, thereby inhibiting c-Cbl-mediated degradation of
Sprouty. Mnk1 is a positive regulator of the Sprouty stability through
serine phosphorylation. c-Cbl canonical Casitas B-lineage lymphoma;
FZD receptor Frizzled receptor; miR-21 microRNA 21; Mnk1 MAPK-
interacting kinase 1; NEDD4 neural precursor cell expressed, develop-
mentally down-regulated 4; PP2A protein phosphatase 2A; PPARγ per-
oxisome proliferator-activated receptor gamma; RTK receptor tyrosine
kinase; Siah2 Seven in Absentia homolog 2;WT1Wilms tumor suppres-
sor 1; CS rearrangement cytoskeletal rearrangement. In this figure, C-
and N-terminus of the Sprouty molecule symbol are shown in white and
blue, respectively
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invaginations involved in multiple cellular functions, includ-
ing signal transduction), Cav-1 similarly inhibits growth fac-
tor activation of ERK in a cell density-dependent manner. At
higher cell densities, Sprouty/Cav-1 interaction modulates
signaling in a growth factor- and Sprouty isoform-specific
manner. At lower cell densities, however, Cav-1 inhibits the
Sprouty function [101]. Moreover, Hwangpo et al. indicated
the interaction between Spry2 and G protein αo/G protein-
regulated inducer of neurite outgrowth (Gαo/GRIN) pathway
in modulating Spry2 repression of ERK [102]. Although
GRIN was shown to bind and sequester Spry2, the activated
Gαo interacted with GRIN to release Spry2.
Sprouty phosphorylation on the conserved tyrosine is con-
sidered as an indispensible prerequisite for the regulatory
function of Spry1 and Spry2 [99, 103], but not for that of
Spry4 [72, 76, 89]. This process, however, is variably induced
by different growth factors. Using NIH3T3 fibroblasts
transfected with Spry1, Spry2 and Spry4 [89], Mason et al.
observed that Spry1, Spry2, but not Spry4 undergo tyrosine
phosphorylation after growth factor stimulation. Moreover,
although FGF induced tyrosine phosphorylation in both Spry1
and Spry2, PDGF and EGF induced it in Spry1 and Spry2,
respectively. Through a time course analysis, they also re-
vealed that FGF-induced tyrosine phosphorylation of Spry1
is kinetically different from that of Spry2. In agreement with
earlier reports [87, 103], the investigators found that tyrosine
phosphorylation regulates interaction of Sprouty with c-Cbl
and concluded that tyrosine phosphorylation serves as a dual
feedback loop which, on the one hand, activates Sprouty
inhibition of ERK and, on the other hand, promotes c-Cbl-
mediated ubiquitination and degradation of Sprouty and thus
terminates signaling inhibition. Functional significance of
Sprouty phosphorylation on other residues than the conserved
tyrosine has also been studied. Rubin et al. [104] observed in
HEK293T cells that FGF, but not EGF, activation of ERK is
inhibited by Spry2 and that only FGF can induce significant
phosphorylation of the C-terminal tyrosines, in particular
Tyr227. On this basis, they postulated that C-terminal tyrosine
phosphorylation modulates the specificity of the Spry2 inhi-
bition of different ERKs. Results from a study by Aranda et al.
supported a functional interaction between dual-specificity
tyrosine phosphorylation-regulated kinase 1A (DYRK1A)
and Spry2 where DYRK1A regulates the phosphorylation
status of Spry2. Since mutation of Thr75 on Spry2, identified
as a phosphorylation site for DYRK1A, enhanced the repres-
sive function of Spry2 on FGF-induced ERK signaling, they
suggested that DYRK1A is a negative regulator of the Sprouty
activity by threonine phosphorylation.
Sprouty dephosphorylation by phosphatases, including
protein phosphatase 2A (PP2A) and Src homology-2 contain-
ing phosphotyrosine phosphatase (SHP2), can differentially
regulate the protein activity. In unstimulated cells, Sprouty is
phosphorylated predominantly on serine residues [6]. Lao
et al. found that PP2A binds and dephosphorylates Spry2 at
Ser112 and Ser115 upon FGF stimulation [105]. They postu-
lated that Spry2 serine dephosphorylation alters the tertiary
structure of the protein and thereby exposes the cryptic
proline-rich motif in the Spry2 C-terminus, which they had
earlier identified as a binding site for Grb2 [106], enabling
Spry2 to potently inhibit FGF activation of ERK. They also
found that PP2A and c-Cbl compete for binding to Spry2 at an
overlapping sequence to fine-tune its activity. They later re-
ported that testicular protein kinase 1 (TESK1) attenuates the
ability of Spry2 to inhibit the growth factor actions in a way
independent of its kinase activity and primarily by interfering
with Spry2/Grb2 interactions and dephosphorylation of serine
residues by PP2A [107]. SHP2 has been implicated in regu-
lating the Sprouty activity through dephosphorylation of the
phosphotyrosines and subsequent dissociation of Sprouty
from Grb2 that positively regulates growth factor activation
of ERK [57, 108, 109]. Pan et al. showed that SHP2 regulates
Sprouty positively at the transcriptional level and negatively at
the post-translational level and concluded that dynamic regu-
lation of Sprouty by SHP2 might be important not only for
modulating Ras signaling in developmental processes, but
also for RTK signaling in general [37]. On the other hand,
Sprouty may mediate its actions in part by increasing active
contents of such phosphatases as protein tyrosine phosphatase
1B (PTP1B) and phosphatase and tensin homolog (PTEN).
Regulating subcellular localization of PTP1B, Sprouty in-
creases PTP1B soluble content which has been shown to
mediate, and mimic, Sprouty-induced repression of cell adhe-
sion and migration [35, 62]. Poppleton et al. reported that
Sprouty, regulates cell migration by inhibiting Rac1 activation
which they postulated, is mediated in part by PTP1B dephos-
phorylation of cellular proteins and, subsequently, decreased
the amount of phosphorylated p130Cas or phosphatidylinositol
3,4,5-trisphosphate (PIP3) known as Rac1 activators [46]. In a
study by Edwin et al. [64], where Spry2 unexpectedly inhibited
EGF activation of AKT and exhibited no significant effect on
EGF activation of EGFR and ERK, they observed that Spry2
increases the amount and activity of PTEN that was found
necessary for Sprouty to attenuate EGF-activated AKT and to
inhibit cell proliferation. Beyond its cytoplasmic role in
negatively regulating PI3K/AKT, PTEN is phosphorylated
and accumulated in the nucleus in response to the Spry2
deficiency to induce p53-mediated growth arrest indepen-
dently of its phosphatase activity [110]. This process is part
of a regulatory mechanism involving Spry2 interaction with
PP2A and PTEN for inhibition of tumorigenesis which will
be discussed later.
2.6 Regulation of RTK activity and stability
Sprouty might regulate activity and stability of RTKs through
interaction with mechanisms involved in reversible (transient)
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and irreversible (definitive) inhibition of ERK on the basis of
dephosphorylation (inactivation) and degradation
(downregulation) of RTKs, respectively. Among the revers-
ible inhibitory mechanisms is the RTK dephosphorylation by
PTP1B that provides spatiotemporal regulation of the RTK
activity [111]. Despite the fact that PTP1B, as described
earlier, is regulated by Sprouty to control some cellular func-
tions on the basis of protein tyrosine phosphorylation, there is
no evidence of direct interaction between Sprouty and PTP1B
in RTK dephosphorylation. In contrast, it is well documented
that Sprouty interferes with c-Cbl-mediated downregulation
of RTK in a growth factor-dependent manner. Sprouty evi-
dently inhibits c-Cbl-induced ubiquitination and degradation
of EGFR, thereby sustaining EGF-activated ERK [7, 87, 103,
112, 113]. Rubin et al. [88] postulated that EGFR activation,
followed by Spry2 phosphorylation and its association with c-
Cbl, initiates a competitive process where c-Cbl promotes
Spry2 polyubiquitination and degradation, and Spry2, con-
versely, sequesters active c-Cbl molecules and impedes recep-
tor ubiquitination and degradation. They concluded that
Sprouty fine-tunes EGF signaling through interlinked positive
and negative feedback loops. Moreover, Edwin and Patel [65]
suggested a novel role for Sprouty in regulating cellular apo-
ptosis where endogenous Sprouty, by sequestering c-Cbl,
augments EGFR activation of ERK and AKT pathways and
the resultant anti-apoptotic signaling. A c-Cbl-independent
mechanism for Sprouty-induced upregulation of EGFR was
identified by Kim et al. [114]. They reported that Spry2
interferes with the trafficking of activated EGFR from early
to late endosomes. To do so, Spry2 was postulated to bind the
endocytic regulatory protein hepatocyte growth factor-
regulated tyrosine kinase substrate (Hrs) to prevent it from
interaction with the tumor susceptibility gene 101 protein
(Tsg101) which is required for EGFR transport.
2.7 Structural variation and functional divergence
of the Sprouty proteins
The C-terminal cysteine-rich (CRD) domain of Sprouty is a
highly conserved region implicated for such key functions of
the protein as a membrane translocation and ERK inhibition
[61, 87, 98, ]. The N-terminal tyrosines Tyr53 (in Spry1 and
Spry4) and Tyr55 (in Spry2) are also conserved residues
crucial for the Sprouty functionality to the extent that their
corresponding dominant-negative mutants fail to attenuate
ERK signaling and even repress the function of the wild type
(WT) protein [60, 72, 76, 89, 99]. Less homologous se-
quences, however, have been localized in the C-terminal as
well as in the N-terminal regions of the Sprouty isoforms that
contribute to their differential interaction with signaling mol-
ecules and molecular partners and accounts, in part, for their
functional divergence. Sprouty isoforms display differential
affinity for different molecular targets upstream or
downstream of Ras or even beyond ERK. Although
interacting with Raf kinases [115–118], Spry2 exhibits the
highest affinity for Grb2. Lao et al. identified an exclusive
proline-rich sequence in the Spry2 C-terminus which was
found as a binding site for Grb2 responsible for differential
interaction of Spry2, as compared to Spry1 and Spry4, with
Grb2 [106]. Sasaki et al. [76] demonstrated that the Spry4
mutants lacking the N-terminal conserved tyrosine residue
necessary for suppressing FGF signaling still inhibit the
VEGF-A-induced activation of ERK in a Ras-independent
manner by binding through the CRD domain to Raf1, indi-
cating that Spry4 differentially regulates different ERK path-
ways through distinct action points. Later, in a study by Ayada
et al. [119], the CRD domain was further implicated for the
Spry4 functions in regulating the VEGF-A-induced, protein
kinase C- (PKC-) dependent activation of ERK, as well as
various types of PLC-dependent signaling. The investigators
indicated that Spry4 interacts through its CRD domain with
PIP2 to inhibit PIP2 hydrolysis and ensuing activation of PKC
in response to VEGF-A. Also found to impact the PKC
downstream signals, Spry4 was introduced as a general inhib-
itor of phospholipase C (PLC) and PLC-dependent signaling
with regulatory functions broader than previously thought
[119]. In a parallel study, investigating the physiological func-
tion of Spry4 as an angiogenic regulator [120], they indicated
that Spry4 suppresses Ras-independent angiogenesis stimu-
lated by VEGF-A and sphingosine-1-phosphate (S1P) while it
does not affect Ras-dependent VEGF-C signaling. TESK1, a
cofilin kinase with critical role in integrin-mediated actin
cytoskeletal reorganization and cell spreading, was identified
by Tsumura et al. [49] as a target for the Spry4 CRD domain
through which Spry4 binds TESK1 and inhibits cofilin phos-
phorylation, thereby negatively regulating cell spreading and
migration independently of its regulatory effect on ERK.
Variation in the binding sites for such molecular partners as
c-Cbl, CIN85, and Cav-1 is also documented. Known to
mediate monoubiquitination of activated RTKs [121–123],
c-Cbl interacts with endocytic scaffold complexes, including
CIN85/endophilins, to facilitate RTK endocytosis and degra-
dation [124–126]. The N-terminal c-Cbl binding motif is
shared by Sprouty isoforms. However, Spry2 exhibits the
highest binding affinity for c-Cbl and Spry4 weakly binds it
[113, 127]. Mason et al. [89] found that tyrosine phosphory-
lation is essential for Sprouty association with c-Cbl and that a
less homologous sequence within the c-Cbl binding motif of
Spry4 prevents it from phosphorylation and binding to c-Cbl.
Furthermore, principal CIN85-binding sites are found only in
Spry1 and Spry2. Haglund et al. showed that Spry2 associates
with c-Cbl and CIN85 upon EGF stimulation to inhibit EGFR
endocytosis and degradation, whereas Spry4 fails to inhibit
downregulation of EGFR [128]. Sprouty isoforms have also
shown differential interaction with Cav-1. Cabrita et al.
showed that although all four Sprouty isoforms can bind
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Cav-1 through their conserved C-terminal domain, they ex-
hibit differential cooperativity with Cav-1 in repressing ERK
[101]. When either Spry1 or Spry3 were expressed in the
presence of Cav-1, FGF-induced ERK activation was syner-
gistically attenuated. However, when either Spry2 or Spry4
were present along with Cav-1, ERK activation increased
slightly compared with when Cav-1 was present by itself,
suggesting a decrease in the inhibitory activity of Cav-1. In
addition, it was shown in another study that inhibitory func-
tion of the Sprouty proteins is enhanced through cooperative
interaction among the protein isoforms. Ozaki et al. [129]
found that all four Sprouty isoforms are able to form hetero-
and homo-oligomers through their C-terminal domains. They
observed that while Spry1 and Spry4 interact with Grb2 and
Sos1, respectively, the hetero-oligomer formed by the two
exhibits the most potent inhibitory effect on FGF-activated
ERK.
3 Deregulation of Sprouty in cancer
Given their critical role as modulators of MAPK/ERK and
mediators of the crosstalk between ERK and other signaling
pathways for maintaining homeostatic control of cellular be-
havior, the Sprouty proteins are conceivably expected to be
deregulated in malignant conditions. On this basis, deregula-
tion of Sprouty in a variety of cancers has been studied by
different investigators and its utility as a biological marker
[21, 69, 110, 130–134 ], a tumor suppressor [41, 52, 66,
135–140], or even an oncogene [55, 68–70, 141, 142] with
application in targeted approaches [13, 52, 56, 69, 131, 134,
143, 144] has been argued which are discussed below.
3.1 Breast cancer
In a study by Lo et al. in 2004, although mSpry1 and mSpry2
were implicated in the breast development during puberty and
pregnancy [21], it was revealed in Cancer Profiling Array
containing pairs of complementary DNAs (cDNAs) generated
from 50 matched pairs of normal and cancer tissues that
hSpry1 and hSpry2 were consistently downregulated in breast
cancer. Real-time PCR confirmed that more than 90 % of the
patient samples demonstrated suppressed expression of Spry1
and Spry2. Neither DNA methylation nor histone
hypoacetylation was found to be responsible for the Sprouty
downregulation by an epigenetic silencing. They finally indi-
cated that the MCF-7 breast cancer cells transfected with a
dominant-negative mutant of Spry2 proliferated faster and
exhibited anchorage-independent growth in vitro and formed
larger tumors in vivo. Following a meta-analysis of the gene
expression profiles of a total of 1,107 tumors combined with a
further analysis of two single datasets, Faratian et al. [132]
reported in 2011 that Spry1, Spry2, and Spry4 were
differentially expressed across clinicopathological subgroups
of the breast cancer and that low Spry2 expression was asso-
ciated with high expression of the human epidermal growth
factor receptor 2 gene (HER2). Spry2 was found as an inde-
pendent prognostic factor that may identify breast cancer
patients with a more favorable outcome even when tumors
exhibit poor pathological features. Since Spry2 was shown to
act synergistically with the HRE2-targeting trastuzumab to
reduce cell viability in vitro, the expression of Spry2 was
quantified in a cohort of 122 trastuzumab-treated patients,
revealing that low Spry2 expression was associated with poor
outcome and increased risk of death. Hence, the investigators
argued for the usefulness of Spry2 in stratifying patients for
treatment with trastuzumab.
Implicating the urokinase-type plasminogen activator re-
ceptor (uPAR) as a partner protein interacting with hSpry1
[145], Mekkawy et al. reported that hSpry1 colocalizes with
uPAR upon stimulation with EGF and urokinase-type plas-
minogen activator (uPA), and suppresses uPAR-mediated mi-
gration and invasion of the MDA-MB-231 breast cancer cells
[59]. Vanas et al. [146] recently indicated that different breast
cancer cell lines differentially express Sprouty as compared
with normal mammary epithelial cells. However, a correlation
between the expression profiles of Spry2 and Spry4 was
found. They also reported that ectopic expression of Spry4
inhibited cell proliferation independently of its endogenous
expression level. Furthermore, increased Spry4 interfered
with serum-induced activation of ERK and inhibited cell
migration.
3.2 Prostate cancer
In 2004, Kwabi-Adoo et al. [143] reported the result of im-
munohistochemical analysis of 407 tissue microarrays con-
taining prostate cancer, as well as matched normal tissue
cores, showing downregulation of hSpry1 in approximately
40 % of the prostate cancer cases studied. This finding was
corroborated by real-time PCR where Spry1 mRNA levels
were significantly decreased in 16 out of 20 prostate cancer
tissue samples in comparison with the normal tissue. In their
in vitro study, the investigators interestingly observed that the
prostate cancer cells LNCaP and PC3, in contrast to primary
epithelial cells, did not show induction of the Spry1 expres-
sion at mRNA and protein levels in response to FGF2 stimu-
lation. They also reported that Spry1 transfection of LNCaP
and PC3 cells had an inhibitory effect on colony formation
and cell proliferation. In agreement with earlier studies show-
ing upregulation of FGFs in prostate cancer, Kwabi-Adoo
et al. concluded that Spry1 downregulation may lead to the
unrestrained FGF-induced signal transduction and hence tu-
mor progression. Later, McKie et al. [135] observed that
Spry2 mRNA is downregulated in invasive prostate cancer
cell lines as well as in clinically high-grade prostate cancers
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when compared to benign prostatic hyperplasia (BPH) and
wel l -d i fferent ia ted prosta te tumors . Ident i fy ing
hypermethylated CpG islands in hSpry2 gene correlated with
suppressed expression of hSpry2 mRNA, they implicated
epigenetic inactivation as the main mechanism for the hSpry2
downregulation in prostate cancer. As later reported by
Kwabi-Adoo et al., this mechanism is also responsible for
downregulation of Spry1 in prostate cancer [147]. Data from
an integrated genomic profiling of 218 prostate tumors by
Taylor et al. revealed that Spry1 and Spry2 genes are
inactivated in 15 and 18 % of the primary cancer, as well as
in 42 and 74 % of the metastatic disease, respectively [148].
Through in situ hybridization on 14 prostate tissue samples
and quantitative real-time PCR analysis in 25 pairs of matched
normal and tumor tissue samples, downregulation of Spry4 in
a subset of prostate cancers was reported by Wang et al. [51].
Their epigenetic analysis revealed methylation of a CpG is-
land in the 5′-regulatory region of Spry4 in more than a half of
all prostate cancer DNA samples studied which was signifi-
cantly correlated with decreased expression of Spry4 mRNA.
They also demonstrated that Spry4, unlike Spry1, does not
hinder cell growth but rather inhibits cell migration, suggest-
ing that Spry1 and Spry4 perform different functions in pros-
tate cancer. Later, Fritzsche et al. [149] observed through
microarray analysis of microdissected prostate tissue speci-
mens a coordinated, yet modest, downregulation of both
Spry1 and Spry2 mRNAs gradually increasing from hyper-
plasia to severe prostatic intraepithelial neoplasia (PIN) to
cancer. Spry2 mRNA downregulation was confirmed in an
independent, larger series of macrodissected tumors by quan-
titative RT-PCR. Unlike McKie et al., however, they reported
that Spry2 downregulation in prostate cancer is independent of
DNA methylation.
ERK and PI3K/AKT have been identified as the two most
commonly altered pathways in prostate cancer with alteration
frequency of 42–43 % in primary and 90–100 % in metastatic
prostate cancer [148]. Activation of ERK and PI3K/AKT by
aberrant RTK signaling has been implicated in the develop-
ment of aggressive prostate cancer [150]. On this basis,
Sprouty interactions with other feedback regulators of the two
pathways and its significance in prostate cancer tumorigenesis
and progression have been explored by some investigators.
PTEN has been reported to be inactivated in 4 % of the primary
prostate cancer aswell as in 42%of themetastatic disease [148].
A key genetic interaction between the Sprouty and PTEN genes
has been reported. Although Pten heterozygosity per se results
in low-grade PIN in mice [151], Schutzman et al. [140] showed
that concomitant inactivation of the Sprouty genes (Spry1 and
Spry2) accelerated emergence of PIN and promoted develop-
ment of more extensive, high-grade phenotype along with the
transition to invasive cancer. Conversely, expression of a Spry2
gain-of-function transgene in the context of Pten homozygosity
suppressed the AKT hyperactivation, and the prostate
tumorigenesis resulted from Pten loss-of-function, implicating
the Sprouty genes in regulation of ERK and PI3K/AKT path-
ways in prostate cancer. They suggested that the expression
status of the PTEN and Sprouty genes in prostate biopsies from
men at risk for prostate cancer could potentially help to risk-
stratify patients with PIN. Patel et al. later indicated that Sprouty
status along with that of PTEN and PP2A collectively represents
an important determinant of the prostate cancer progression
[110]. They showed in a coherent set of in vitro and in vivo
systems that although Spry2 deficiency is sufficient to activate
both PI3K/AKT and ERK cascades, it is insufficient to drive
tumorigenesis with Spry2-deficient cells exhibiting PTEN-
mediated growth arrest. As follows, it was shown that the Spry2
deficiency-induced growth arrest mechanistically involves
PTEN, PP2A, glycogen synthase kinase 3 beta (GSK3B), p53,
and reactive oxygen species (ROS). By enhancing RTK activa-
tion, Spry2 deficiency increases intracellular ROS which subse-
quently activates PP2A. PP2A then dephosphorylates and acti-
vates GSK3B that drives phosphorylation and nuclear accumu-
lation of PTEN. Nuclear PTEN eventually promotes growth
arrest by induction of p53 and p21, independent of its phospha-
tase activity. Overall, by introducing a novel, PP2A-dependent
tumor suppressor checkpoint, Patel et al. identified the cooper-
ative role of concomitantly inactivated Spry2, PTEN, and PP2A
to drive the prostate cancer progression. Hence, they postulated
that loss of Spry2 may represent an early event in prostate
carcinogenesis compensated by nuclear PTEN-mediated growth
arrest which might be subsequently overcome by inactivation of
PTEN, TP53, or PP2A.
3.3 Liver cancer
In a gene expression study by Chen et al. in 2002, Spry2 was
among the top 600 genes found to be differentially expressed
in hepatocellular carcinoma (HCC) compared with non-tumor
liver tissue [152]. In 2006, a more stringent and biologically
relevant analytic approach to the same database by Fong et al.
revealed a consistent downregulation of Spry2 in HCC [50].
Using in situ hybridization on tissue microarrays from an
independent set of patients, they confirmed significantly dif-
ferential expression of Spry2 in HCC compared with normal
or cirrhotic liver tissue. Although showing the resemblance
between the expression pattern of Spry2 and that of several
potential tumor markers in hepatocellular carcinoma, the in-
vestigators ruled out loss of heterozygosity (LOH) or the
promoter hypermethylation as possible mechanisms responsi-
ble for Spry2 downregulation. Moreover, it was shown that
Spry2 plays functionally important roles in HCC by inhibiting
hepatocyte growth factor (HGF)-induced cell prolifera-
tion and ERK activation in the Spry2-overexpressing
HCC cells.
Identifying Spry2 in their genomic analysis as a downreg-
ulated and frequently deleted gene in HCC, Lee et al. [66]
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observed in vitro that overexpressed Spry2 inhibits HCC cell
growth. Their in vivo study using hydrodynamic transfection
not only exhibited, in line with earlier studies [153, 154], the
cooperative role of activatedWnt/β-catenin and Ras in induc-
tion of HCC, but also revealed that dominant negative Spry2
cooperates with β-catenin to induce development of liver
cancer in mice, with tumor cells showing upregulation of
ERK and deregulation of genes involving in cell proliferation,
apoptosis, and angiogenesis. This study suggested that Spry2
might function as a tumor suppressor in HCC. They reported
later the synergistic role of Spry2 inactivation and c-Met
upregulation in mouse and human hepatocarcinogenesis
[155]. They observed in a collection of human liver tissue
samples the significant downregulation of Spry2 protein as
well as ubiquitously high expression of c-Met (total and
activated) and its downstream effectors (activated Erk and
Akt) in most cases of HCC with poorer outcome (HCCP) in
the context of WT Ras. The expression of Spry2 was found to
be downregulated at transcriptional and post-translational
levels by promoter hypermethylation, LOH, and proteasomal
degradation by NEDD4. In vitro, Spry2 overexpression
inhibited c-Met-induced cell proliferation as well as ERK
and AKT activation, whereas loss of Spry2 potentiated c-
Met signaling. Their in vivo study with mice hydrodynami-
cally transfected with c-Met and/or a dominant negative mu-
tant form of Spry2 indicated that Spry2 inactivation cooper-
ates with c-Met to induce hepatocarcinogenesis by sustaining
proliferation and angiogenesis, suggesting a pivotal oncogenic
mechanism responsible for unrestrained activation of ERK
and AKT pathways in human hepatocarcinogenesis. By hy-
drodynamic injection and coexpression of an activated/
myristoylated form of Akt (myr-Akt) and a dominant negative
Spry2 mutant in the mouse liver, Wang et al. [71] later indi-
cated that loss of Spry2 accelerated AKT-induced
hepatocarcinogenesis which was associated with activation
of ERK pathway and pyruvate kinase M2 (PKM2)-induced
glycolysis. In vitro, they found that activation of PKM2 in the
HCC cell line HLE transfected with Akt and dominant nega-
tive Spry2 is independent of ERK and AKT cascades, collec-
tively implying that loss of Spry2 synergizes with activated
AKT to induce rapid hepatocarcinogenesis through the acti-
vation of ERK and PKM2 pathways.
Differential expression of the Sprouty homologs in HCC
was reported by Sirivatanauksorn et al. [133], where paired
HCC and non-tumor liver tissue samples from 31 patients
were examined by quantitative RT-PCR. Most HCC tissues
showed upregulation of Spry1 and downregulation of Spry2
and Spry4 at mRNA level. Moreover, mRNA expression of
Spry1, Spry2, and Spry4 in cancerous specimens was signif-
icantly different from that in nontumor tissues. The expression
of Spry3, however, did not show any significant difference
among the samples. Studying the association of the Sprouty
gene expression with clinical parameters of HCC, they
indicated that the expression of Spry2 was significantly lower
in patients with advanced disease and angiolymphatic inva-
sion, whereas Spry1 was significantly upregulated in cases
without underlying cirrhosis compared with cirrhotic patients.
Prognostic significance and clinical relevance of the Spry2
protein expression in HCC was later studied by Song et al.
[134]. Their initial study in vitro showed that the ratio of
phospho-ERK to Spry2 in the HCC cell lines MHCC97L,
HCCLM3, and HCCLM6 displayed an elevation concordant
with their stepwise metastatic potential. Similarly, the Spry2
expression per se inversely correlated with the metastatic
potential of the HCC cells. In their immunohistochemical
study, they found that 86.3 % of a total of 240 patients
exhibited Spry2 downregulation. They reported that Spry2
downregulation accompanied highly malignant clinicopatho-
logical features like advanced TNM stages and tumors with
vascular invasion and poor differentiation. They found that
Spry2-negative patients had poorer survival and increased
postoperative recurrence, and thereby suggested potential im-
plications of Spry2 as a predictor of the disease prognosis and
a biomarker of the treatment sensitivity.
3.4 Lung cancer
Using reverse transcription-PCR and immunohistochemical
staining of matched tumor and nontumor samples, Sutterluty
et al. reported in 2007 that Spry2 expression, but not that of
Spry1, is consistently reduced at mRNA and protein levels in
non-small cell lung cancer (NSCLC) tissues [52]. Their in vitro
analysis with a panel of NSCLC cell lines revealed that high
levels of Spry2 expression were exclusively detected in
KRAS-mutated cells and that only few cell lines with reduced
Spry2 exhibited Spry2 promoter hypermethylation.Moreover,
although ectopic expression of Spry2 inhibited ERK activity
and diminished cell migration in NSCLC cells with WT
KRAS, but not in those with the mutated one, it significantly
reduced cell proliferation in all NSCLC cell lines studied
in vitro and blocked tumor formation in mice inoculated with
the KRAS-mutated cell line A-549. In addition, even a dom-
inant negative Spry2 mutant defective in antagonizing ERK
significantly, although less potently, inhibited cell prolifera-
tion in NSCLC cells with or without KRAS mutation. Collec-
tively, they demonstrated that Spry2 downregulation contrib-
utes to NSCLC tumorigenesis via ERK-dependent and ERK-
independent mechanisms and implicated Spry2 as a tumor
suppressor in NSCLC. Consistently, Shaw et al. reported that
Spry2 functions as a tumor suppressor in the context of a
germline oncogenic KRASmutation—KRASG12D—in which
loss of Spry2 increased the number and overall burden of lung
tumors in mice [31]. This was corroborated by a later report
whereby lack of Spry2 expression along with high level of
ERK activation was evident in putative tumorigenic cells of
KRASG12D-induced neoplasia in mouse lungs [156]. The role
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of Spry2 in inhibiting lung tumor development was further
confirmed by Minowada et al. [144] who evaluated conse-
quences of Spry2 overexpression in mouse lung epithelium in
the context of urethane-induced tumorigenesis. The chemical
carcinogen urethane induces KRAS gain-of-function muta-
tions and lung tumors in mice. The investigators observed
that Spry2 overexpressing animals developed significantly
fewer and smaller tumors compared with their littermate con-
trols. Since the overexpression of Spry2 did not alter KRAS
mutational frequencies, it was suggested that the tumor-
suppressing activity of the overexpressed Spry2 might be
applied at stages of carcinogenesis subsequent to KRAS
mutation.
A putative role for Spry4 as part of Wnt7A/Fzd9 tumor-
suppressing pathway was initially suggested by Winn et al.,
where Wnt7A and Fzd9 induced the expression of Spry4 in
NSCLC cells [136]. They subsequently identified PPARγ
[157, 158] and Spry4 [56] as downstream effectors of
Wnt7A/Fzd9 that mediate its anti-tumorigenic effects.
Reporting downregulation of Spry4 in a variety of NSCLCs
as well as in dysplastic lung cell lines, Tennis et al. showed
that Spry4 transfection inhibited NSCLC cell growth, migra-
tion, invasion, and epithelial-mesenchymal transition. They
found that Wnt7A/Fzd9 signaling increases Spry4 promoter
activity through PPARγ. Corroborated by their earlier reports
[158, 157, 136], Tennis et al. concluded that Spry4 represents
an inducible effector of the Wnt7A/Fzd9 pathway down-
stream of PPARγ which restores a nontransformed epithelial
phenotype while inhibiting NSCLC cell growth, migration,
and invasion [56].
3.5 Colon cancer
In their cDNA array study on different cancers in 2004, Lo
et al. presented differential expression pattern of Spry2 in 38
matched pairs of normal and tumor samples from colon cancer
patients [21]. In a BLAST search of human ESTs followed by
in silico expression analysis, Katoh and Katoh [13] observed
that Spry4 mRNA is expressed in colon cancer. Based on the
comparative genomics analyses, they characterized Spry4 as
the evolutionarily conserved target gene of the Wnt/β-catenin
signaling pathway. Implicating Spry4 in Wnt/β-catenin regu-
lation of progenitor cells, they suggested that epigenetic si-
lencing and loss-of-function mutations of Spry4 could lead to
carcinogenesis. In a study by Barbachano et al. [69], immu-
nofluorescence analysis of human colon cancer biopsies quan-
titatively confirmed in 34 patients showed high levels of
Spry2 and low levels of E-cadherin in undifferentiated, high-
grade tumors in contrast to low levels of Spry2, and high
levels of E-cadherin in low-grade specimens. In vitro, Spry2
and E-cadherin exhibited an inverse correlation and reciprocal
regulation in colon cancer cells. The investigators found that
Spry2 induces the expression of the ZEB1 epithelial-to-
mesenchymal transition gene and protein and abrogates the
induction of an adhesive epithelial phenotype by
1,25(OH)2D3. Supplemented by a meta-analysis of the data
available at the Oncomine database [159] in favor of higher
expression of Spry2 in colon tumors compared with other
neoplasias, their results suggested a tumorigenic action and a
potential role as a tumor marker for Spry2 in colon cancer.
Examining a low number of matched colon cancer samples,
Holgren et al. [68] also reported upregulation of Spry2, as well
as c-Met, at mRNA and protein levels. In vitro, Spry2 upreg-
ulation in the KRAS-mutated cell line HCT-116 significantly
increased cell proliferation, accelerated cell cycle transition
and enhanced cell migration and invasion which were attrib-
uted, at least in part, to activation of HGF/c-Met axis and its
downstream effectors Akt and Erk. They also demonstrated
that Spry-2 knockdown significantly inhibited cell invasion in
bothWT- andmutant KRAS-expressing cell lines.With Spry2
transfectants forming significantly larger xenografts with
higher metastatic potential in vivo, they concluded that Spry2
may control metastatic potential of colon cancer cells, at least
in part, by c-Met upregulation. Examining primary tumor
samples from 113 patients with colorectal cancer, Watanabe
et al. [160] later observed that KRAS mutant tumors (31 %)
exhibited a distinct gene expression signature compared with
their WT counterparts (69 %) where Spry2 was among the 30
genes upregulated in the KRAS mutants. They found that the
discriminating genes identified were related to not only K-
Ras/ERK but other signaling pathways such as Wnt/β-
catenin, NF-kappa B activation, and TGFβ signaling, thereby
suggesting a crosstalk between K-Ras-mediated signaling and
other pathways in colorectal cancer.
In contrast, Feng et al. reported in 2010 that Spry2may be a
potential biomarker in predicting the response to anti-EGFR
treatment in colon cancer [131]. They showed that the expres-
sion of Spry2 positively correlates with the sensitivity of colon
cancer cells to the EGFR inhibitor gefitinib and that Spry2 can
enhance the response of colon cancer cells to gefitinib by
increasing the expression of phosphorylated EGFR, total
EGFR, and PTEN. They later reported downregulation of
Spry2 in association with colon cancer progression and sug-
gested a tumor suppressor role for Spry2 [137]. By real-time
quantitative RT-PCR on mRNA isolated from normal and
tumor tissues of 67 patients with colon cancer, they showed
that Spry2 was downregulated in 72.7 % (16/22) of stage II,
91.3 % (21/23) of stage III, and 100 % (22/22) of stage IV
tumors examined. A negative correlation was also evident
between the expression levels of Spry2 and the microRNA
miR-21, an indicator of poor survival and poor response to
adjuvant chemotherapy in cancer patients. In vitro,
overexpressed Spry2 inhibited the growth and migration of
HCT116 human colon cancer cells which was concomitantly
accompanied by an increase in the expression of PTEN and
reduction in phosphorylation of ERK and Akt. Spry2 also
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suppressed the growth and tumorigenesis of colon cancer cells
in vivo. In line with earlier studies suggesting Sprouty genes as
targets of miR-21 [161–163], they proposed that Spry2 is
negatively regulated by miR-21 and that such interaction
may play a role in colon cancer carcinogenesis. Spry1, too,
was later found to inhibit EGF- or uPA-induced migration of
HCT116 cells in vitro [59].
3.6 Melanoma
Examining a panel of melanocytic and melanoma cell lines,
Tsavachidou et al. reported in 2004 that Spry2 acts as an
inhibitor of ERK signaling in melanocytes and WT BRAF
melanoma cells, but not in cell lines with BRAFV600E (previ-
ously designated as BRAFV599E) mutation [117]. Their genet-
ic and gene expression analyses revealed that Spry2 is down-
regulated in melanoma cells harboring WT BRAF yet upreg-
ulated in the BRAFV600E mutants. They observed that Spry2
directly interacted with WT B-Raf and inhibited ERK but
failed to directly bind the mutant B-Raf and did not affect
ERK. In conclusion, they proposed that Spry2 may be
bypassed in melanoma cells either by downregulation of its
expression in WT BRAF cells or through BRAF mutation. In
a later study [164], microarray data validated by real-time
PCR indicated upregulation of Spry2 in melanoma cell lines
withmutations in BRAF andNRAS. Qi et al. [95] showed that
the expression of a dominant-negative Siah2 RING finger
mutant in SW1 mouse melanoma cells reduced their tumori-
genesis through the increase of Spry2. Using genomic and
gene expression analyses of an animal model of skin neo-
plasm that produces both benign and malignant tumors,
Quigley et al. [165] demonstrated that alleles that are not
relevant in normal tissue are associated with tumor suscepti-
bility but somatic alterations during tumor progression may
reduce the detectable influence of germline polymorphisms.
As such, although Spry2 was identified as a susceptibility
gene for skin tumors and was expressed at very low levels in
normal skin and at elevated levels in tumors, higher Spry2
expression in tumors was found to be associated with greater
resistance to tumorigenesis which was ascribed to the role of
Spry2 in regulation of ERK. Through an integrative approach
analyzing genomic and gene expression changes in relation to
in vivo growth aggressiveness, Mathieu et al. [166] found that
genomic loss of Spry1 and Spry2—along with altered expres-
sion of some other genes—was associated with a more ag-
gressive melanoma phenotype. However, no convincingly
enhanced levels of ERK phosphorylation were found in the
fast-growing subgroup of their melanoma model compared
with its slow-growing counterpart. Given widespread activat-
ing mutations in BRAF and, in particular, inability of Spry2 to
attenuate ERK in the context of BRAFV600E mutation, their
findings argue for a role of Sprouty in regulation of melanoma
aggressiveness independent of attenuation of ERK.
3.7 Sarcoma
In 2005, gene expression profiling of 134 human sarcoma
tumors by Baird et al. revealed upregulation of Spry2 in 2/7 of
fibrosarcomas and 4/5 of dermatofibrosarcomas [167]. Lito
et al. reported upregulation of Spry2 protein in the human
fibrosarcoma cell lines SHAC, HT1080, VIP:FT and NCI as
well as in HRAS- and NRAS-transformed human fibroblasts
[141]. They provided evidence that Spry2 is necessary for
sarcoma formation by patient-derived fibrosarcoma cell lines
or HRAS oncogene-transformed human fibroblasts through
EGFR signaling. Indicating Spry2-dependent interaction of
H-Ras with c-Cbl and CIN85, and the ability of Spry2 to
sustain EGFR signaling and tumor formation in the context
of HRAS activation, they indicated that the positive effect of
Spry2 in sarcoma tumor formation by human fibroblasts is
specific to HRAS transformation. Contrasting the role of
Spry2 in HRAS transformation with that earlier reported in
KRASG12D mutation [31], Lito et al. raised the possibility of
the differences among oncogenic Ras isoforms in regulation
of tumorigenesi resulted from Ras isoform-specific modes of
action [141]. Using a similar model system, they later showed
that oncogenic HRAS requires Spry2 to protect fibroblasts
from UV-induced apoptosis and damage and to resist
cisplatin cytotoxicity. This antiapoptotic function of Spry2
was found to be mediated by a pathway consisting of Akt,
human double minute 2 (HDM2), and p53 recruited
through Rac1 [55]. In another study, gene expression
profiling by Schaaf et al. [70] revealed that Spry1 and
Spry2, and Spry4 were consistently upregulated in the
embryonic subtype of rhabdomyosarcoma (ERMS) as
compared with its alveolar subtype (ARMS). They indi-
cated that elevated Spry1 in ERMS cells associated with
hyperactive ERK signaling is caused by oncogenic RAS
mutations which is frequent in ERMS but absent in
ARMS. Spry1 was found essential for ERMS cell prolif-
eration and survival in vitro and ERMS tumor formation
and maintenance in vivo. Accordingly, silencing of Spry1
abolished tumorigenicity of ERMS cells and caused re-
gression of established ERMS tumors in mice. Thus, they
argued that Spry1 functions as an agonist of ERK signal-
ing in rhabdomyosarcoma with RAS mutation.
A microarray analysis of 41 soft tissue tumors reported by
Nielsen et al. in 2002 [168] revealed that Spry1, Spry4, and
KITwere among the genes that demonstrated specific expres-
sion in gastrointestinal stromal tumors (GISTs). Using expres-
sion profiling of the GIST882 cells treated with the c-Kit
inhibitor imatinib in vitro, Frolov et al. later identified Spry4
as an imatinib-responsive gene significantly downregulated in
the treated cells and the Spry4 protein as a downstream
effector of the c-Kit-activated ERK targeted by the drug
[130]. In their clinical study, since Spry4 levels were dramat-
ically decreased in patients responsive to the drug compared
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with non-responsive patients, the authors proposed Spry4 as a
reliable marker of the imatinib-responsive treatment.
Sprouty, on the other hand, has reportedly shown inhibitory
effects on other types of sarcoma cells and tumors. Identifying
Spry2 as an inducible, negative regulator of HGF/SF-induced
activation of ERK and AKT, Lee et al. [63] reported in 2004
that Spry2 inhibits proliferation, anchorage-independent
growth, migration, and invasion of SK-LMS-1 human
leiomyosarcoma cells in vitro. Rathmanner et al. reported that
Spry2, but not Spry4, potently inhibits proliferation and inter-
fere with migration of human osteosarcoma-derived cells,
with the N-terminal sequence variation being implicated in
the specific inhibitory effect of Spry2 [169]. Osteosarcoma
cell invasion was also shown to be impeded by overexpressed
Spry1 as a result of interaction with uPAR [59]. A microarray
study by Holtkamp et al. [170] identified Spry2 as one of the
genes differentially upregulated in benign human neurofibro-
ma as compared with malignant peripheral nerve sheath tu-
mors (MPNST) from the same patient. Supporting a role for
Sprouty in limiting the development of these benign lesions,
Courtois-Cox et al. later reported that Sprouty genes were
highly expressed in both Raf-expressing and neurofibromin
1 (NF1)-deficient fibroblasts [171]. They argued that Sprouty
is part of a multifaceted negative feedback signaling network
in response to the aberrant activation of Ras that underlies
oncogene-induced senescence.
3.8 B-cell lymphoma
Reported in 2008, epigenetic silencing of hSpry2 and its
clinical relevance in lymphoid/hematopoietic malignancies
were investigated by Sanchez et al. [172]. Of 16 relevant
human cancer cell lines, hSpry2 promoter was methylated
only in the B-cell diffuse lymphoma cell line HT. This was
found to be associated with and related to hSpry2 downregu-
lation at mRNA and protein levels. The ectopic expression of
hSpry2 in HT cells drastically reduced the phorbol 12-
myristate-13-acetate (PMA)-induced activation of ERK. The
investigators then observed that HT mock cells developed
tumors in nude mice seven times larger than those formed
by the hSpry2 transfectants. Clinically, they identified hSpry2
hypermethylation in 26 out of 71 patients with B-cell diffuse
lymphoma as well as in 10 out of 13 Burkitt’s lymphomas but
in no normal B lymphocytes from 37 healthy individuals. As
evaluated in 55 out of the initial 71 patients, the authors
reported that Spry2 promoter hypermethylation was signifi-
cantly associated with a lower 5-year survival rate and con-
cluded that Spry2 could be an important regulator in mouse B-
cell diffuse lymphomas. In agreement, epigenetic silencing
and repressed expression of Spry2 in mouse and human ma-
ture B-cell tumor cell lines and a T-cell leukemia 1-transgenic
(TCL1-tg) mouse model of B-cell lymphoma as well as in
human B-cell lymphoma samples were reported by Frank
et al. [67]. Five out of seven diffuse large B-cell lymphomas
and the only Burkitt’s lymphoma sample studied contained
DNA methylation of the Spry2 promoter which was associat-
ed with repressed Spry2 expression in 4 out of 6 lymphoma
samples. Mechanistically, they demonstrated that Spry2 over-
expression reduces ERK activation and induces B-cell apo-
ptosis and Spry2 inactivation, on the other hand, increases
ERK-dependent proliferation of B-cells. In conclusion, they
implicated Spry2 in regulation of TCL1-augmented ERK
signaling and B-cell proliferation and suggested Spry2 epige-
netic silencing as an aberration contributing to B-cell lympho-
ma progression.
3.9 Testicular germ cell cancer
Results from a genome-wide scan among 277 cases of testic-
ular germ cell tumors (TGCT) and a subsequent replication
study on 371 cases were reported by Kanetsky et al. in 2009
[142] whereby genetic variation of KITLG (gene encoding the
ligand for the receptor tyrosine kinase c-KIT) and Spry4 was
shown to predispose to testicular germ cell cancer. These
findings were found in agreement with an earlier report iden-
tifying Spry4 as downstream of c-KIT activation of ERK
which is upregulated in GISTs in association with aberrant
activation of c-KIT [130].
3.10 Endometrial cancer
Differential expression of Spry2 in normal endometrium
throughout the menstrual cycle as well as in endometrial
cancer was reported by Velasco et al. [41] in 2011. Indicating
a complete absence of Spry2 in about 20 % of 136 cases
immunohistochemically studied, they found that Stage III
and IV tumors had the lowest levels of Spry2 immunostain-
ing.Moreover, a strong, inverse correlation between the Spry2
expression and the cell proliferation index Ki67 was revealed,
with nonendometrioid carcinomas (NEEC) exhibiting the
highest level of cell proliferation and lowest level of the Spry2
expression. They concluded that Spry2 may be involved in
regulation of endometrial carcinogenesis through control of
cell proliferation.
3.11 Thyroid cancer
In 2012, Macia et al. [139] reported that Spry1 is expressed in
mouse thyroid C-cells and that targeted deletion of Spry1
causes C-cell hyperplasia, a precancerous lesion preceding
medullary thyroid carcinoma (MTC), in young adult mice.
They also found that ectopic expression of Spry1 in a tumor-
igenic, MTC-derived cell line reduced proliferation of the
cancer cells in vitro and inhibited growth of the xenografts
in vivo. Furthermore, they indicated that the Spry1 promoter is
frequently methylated and that the Spry1 expression is
710 Cancer Metastasis Rev (2014) 33:695–720
accordingly decreased in human MTC samples, collectively
suggesting that Spry1 is a candidate tumor-suppressor gene in
MTC. By in vivo analysis of the thyroid glands from the Spry1
knockout mice, they recently described a novel mechanism by
which Spry1 induces a senescence-associated secretory phe-
notype via activation of the NF-kappaB pathway, thereby
restricting cell proliferation independently of the ERK path-
way [173].
3.12 Pituitary tumor
Investigating the role of the C-terminal binding protein
(CtBP), a transcriptional corepressor with known oncogenic
properties, in normal and neoplastic pituitary, Dorman et al.
[138] identified Spry2 as a potential target of CtBP1 and hence
a potential tumor suppressor involved in regulation of pitui-
tary cell growth and apoptosis. Gene expression profiling
validated by real-time PCR andWestern blotting revealed that
Spry2 is upregulated in the CtBP1-deficient GH4 pituitary
tumor cells that grow slower than their parental cells. Mech-
anistically, upregulation of Spry2 in CtBP1-deficient GH4 cell
was shown to impair phosphorylation of the fibroblast growth
factor receptor substrate 2 (FRS2α) in response to FGF.
3.13 Ovarian cancer
In a study by Polytarchou et al. [174], Spry1 was identified as
a target of miR-21 in Akt2-conferred resistance to hypoxia in
both normal and tumor cells. Upon oxygen deprivation, Akt2
was found to induce miR-21 which in turn targets and
downregulates Spry1, PTEN, and programmed cell death 4
(PDCD4) led to enhanced survival of Akt2-expressing cells
during hypoxia. They provided evidence that this hypoxia-
activated, Akt2-dependent pathway is present in ovarian can-
cer through examining a panel of ovarian cancer cell lines
in vitro as well as real-time PCR analysis of 31 human ovarian
cancer samples. In their initial report of an ongoing investiga-
tion into the role of Sprouty in ovarian cancer, Masoumi-
Moghaddam et al. later documented differential expression
of Spry1 and Spry2 in a panel of ovarian cancer cells where a
tendency for downregulation of Spry1 and/or Spry2 was
evident [175].
3.14 Clear cell renal cell carcinomas (ccRCC)
In an attempt to identify genes effectively discriminating
between clinically aggressive and nonaggressive ccRCC,
Takahashi et al. performed the gene expression profiling of
29 tumors obtained from patients with diverse clinical out-
comes. According to their report, Spry1 was exclusively up-
regulated in the good outcome group [176].
In conclusion, the contributory role of the Sprouty down-
regulation in carcinogenesis and/or tumor progression and
metastasis in the context of the breast [21], prostate [110,
135, 140, 147], liver [66, 71, 155], lung [31, 52, 56, 144,
157, 158], colon [13, 137], melanoma [95, 165, 166], B-cell
lymphoid [67, 172], and thyroid [139, 173] cancer is docu-
mented. This contribution is an apparent reflection of the
critical role of Sprouty in regulation of cellular processes
central to the development, progression, and dissemination
of malignant conditions, including cell proliferation, migra-
tion, invasion, transformation, and survival (Table 2). Mech-
anistically, Sprouty regulates cell behavior through modula-
tion of the ERK activation along with interaction with a wide
range of players and ultimate involvement of other regulatory
mechanisms and cellular pathways as depicted in Figs. 2 and
3. Nevertheless, context-dependent contribution of Sprouty to
cancer tumorigenicity and metastatic potential has also been
reported in colon cancer [68, 69], as well as in RAS mutated
fibrosarcoma [141] and rhabdomyosarcoma [70] as a result of
E-cadherin repression and ensuing inhibition of the adhesive
epithelial phenotype [69], upregulation of c-Met [68], and a
concomitant RAS mutation [70, 141].
4 Sprouty in cancer: Complexity and controversy
Under physiological conditions, as detailed earlier, Sprouty-
mediated regulation is complex and multifaceted. Despite the
initial understanding of Sprouty as a negative regulator of
ERK, it is now evident that Sprouty has targets beyond ERK
and functions, in concert with a variety of interacting mole-
cules, in a cell- and context-dependent manner. Sprouty is
differentially expressed by various normal cells not only dur-
ing development, but also in adult organs in a tissue-specific
or ubiquitous manner. Moreover, different Sprouty isoforms
exhibit divergent regulatory functions. On this basis, it is not
surprising that role of Sprouty in malignant conditions, where
physiological homeostasis is altered in favor of neoplastic
growth and progression, is fraught with intricacy and contro-
versy. As discussed throughout this article, attempts have been
made to shed light on unknown aspects of this story. In sum,
our current knowledge indicates that the Sprouty’s implication
in cancer, similar to its role under normal circumstances, is cell
type- and context-dependent. Although deregulation of the
Sprouty genes can indicate a general aspect of the Sprouty
status in a given cancer, this needs to be interpreted in relation
to the gene expression at the protein level and pertinent
functional outcomes. A rewired genetic network with the
involvement of Sprouty and ERK signaling apparently pro-
motes tumorigenesis. However, the Sprouty gene association
with tumor susceptibility or resistance may not be necessarily
associated with a consistent phenotype in vivo due to somatic
alterations. Thus, a combination of genetic and gene expres-
sion analysis has been recommended to complement genetic
association methods for identification of susceptibility or
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resistance factors [165]. The expression of the Sprouty pro-
teins, on the other hand, might be variably altered during
tumorigenesis based on the pathogenic mechanism involved.
Therefore, the expression pattern of Sprouty might be
reflecting, for instance, a response to the mutant RAS-
induced hyperactivation of ERK or, on the contrary, the
Fig. 2 Schematic illustration of the Sprouty-mediated regulation of cell
proliferation, differentiation, and survival irrespective of the Sprouty iso-
form and cell type. Sprouty activity is resulted from or regulated through
interaction with a number of players. This interaction impacts functionality
of ERK and other signaling pathways. Sprouty binds c-Cbl and CIN85 and
sequestrate c-Cbl to augment and prolong RTK signaling by inhibiting
receptor endocytosis. This mechanism has been implicated in cell differen-
tiation. E3 ubiquitin ligase c-Cbl, on the other hand, binds and induces
degradation of Sprouty to restrict ERK activation. Sprouty has also been
shown to interact with different phosphatases. It increases active contents of
PTEN to mediate antiproliferative actions by inhibiting Akt activation.
PTEN is also phosphorylated and accumulated in the nucleus in response
to the Sprouty deficiency to induce p53-mediated growth arrest indepen-
dently of its phosphatase activity. It is likely that the proto-oncogenic
potential of NEDD4 is resulted in part from its ability to ubiquitinate both
Sprouty and PTEN, resulting in unchecked activation of Akt. Sprouty also
increases PTP1B content. However, there is no evidence of direct interac-
tion between Sprouty and PTP1B inRTK dephosphorylation. Phosphatases
PP2A and SHP2 differentially regulate the Sprouty activity. Although
PP2A potentiates Sprouty binding to Grb2 and thus positively regulates
Sprouty by serine dephosphorylation, SHP2 promotes dissociation of
Sprouty fromGrb2 through tyrosine dephosphorylation and checks Sprouty
inhibition of ERK. Moreover, interaction between Sprouty and kinases
yields different outcomes. DYRK1A is considered a negative regulator of
the Sprouty activity by threonine phosphorylation. TESK1 interferes with
Sprouty/Grb2 interaction as well as with Sprouty serine dephosphorylation
by PP2A, thereby attenuating Sprouty functioning. Sprouty isoforms also
exhibit differential cooperativity with Cav-1 to repress growth factor acti-
vation of ERK. At low cell density, however, Cav-1 inhibits the Sprouty
function. Sprouty is a general inhibitor of PLC-dependent signaling and
inhibits various PKC upstream and downstream signals, including PIP2
hydrolysis. Sprouty is an interacting partner of the Gαo/GRIN pathway.
GRIN modulates Sprouty repression of ERK by binding and sequestering
Sprouty. Activated Gαo, on the other hand, promotes inhibition of ERK via
interacting with GRIN and releasing Sprouty. Finally, interaction among the
Sprouty isoforms is a mechanism through which oligomers with more
potent activity can form.CavCaveolin-1; c-Cbl canonical Casitas B-lineage
lymphoma; CIN85 Cbl-interacting protein of 85 kDa; DYRK1A dual-spec-
ificity tyrosine-phosphorylated and -regulated kinase 1A; Gαo G protein
αo; GRIN G protein-regulated inducer of neurite outgrowth; miR-21
microRNA 21; Mnk1 MAPK-interacting kinase 1; NEDD4 neural precur-
sor cell expressed, developmentally down-regulated 4; PAPC paraxial
protocadherin; PIP2 phosphatidylinositol-4,5-bisphosphate; PKC Protein
kinase C; PLC phospholipase C; PP2A protein phosphatase 2A; PTEN
phosphatase and tensin homolog; PTP1B protein tyrosine phosphatase 1B;
RTK receptor tyrosine kinase; SHP2 Src homology-2 containing
phosphotyrosine phosphatase; Siah2 Seven in Absentia homolog 2; TESK1
testicular protein kinase 1;HCD high cell density; LCD low cell density. In
this figure, C- andN-terminus of the Sproutymolecule symbol are shown in
white and blue, respectively. Red lines indicate the Sprouty effect, with
dashed lines representing indirect influence. Question marks refer to pos-
tulated, but not proven, interactions
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epigenetic silencing of the Sprouty promoter. Moreover,
Sprouty’s mode of action can be converted under malignant
conditions. In the context of the RAS mutation, for example,
Sprouty can function as an inhibitor [31, 52, 171] or facilitator
[55, 68, 70, 141, ] of the tumor development and/or progres-
sion. This might be resulted in part from different functionality
of the RAS isoforms [141].
Collectively, the expression pattern of Sprouty in different
types of cancer is just a reflection of the primary or secondary
deregulations incurred under specific circumstances. Since
Sprouty is physiologically able to function as both a repressor
and an activator of RTK signaling, its specific implication
needs to be individually investigated in different cancers
where its mode of action be evaluated in relation to the
malignant cell behavior. In this regard, although investigation
of the Sprouty gene aberrations and relevant oncogenic
mutations can provide clues to the underlying mechanisms,
evaluation of the effect of the Sprouty expression on cancer
cell biology along with analysis of the clinicopathological
relevance of the Sprouty deregulation will yield a better un-
derstanding of the Sprouty biology in a given cancer with
potential application in the Sprouty-based approaches.
5 Conclusion
Initially discovered as a growth factor antagonist with in-
volvement in developmental processes, Sprouty is now rec-
ognized as a versatile modulator of ERK that also impacts
other pathways to control crucial physiological processes in
interaction with an increasing number of effectors, mediators,
Fig. 3 Schematic illustration of the Sprouty-mediated regulation of cell
migration, adhesion, and cytoskeletal rearrangement irrespective of the
Sprouty isoform and cell type. Sprouty is shown to interact with phos-
phatases. It increases active contents of PTP1B to mediate its
antimigrative action by inhibiting activation of Rac1. Sprouty inhibits
the kinase activity of TESK1 that plays a critical role in integrin-mediated
actin cytoskeletal reorganization and cell spreading. Sprouty is a general
inhibitor of PLC-dependent signaling and inhibits various PKC upstream
and downstream signals. Protocadherin PAPC implicated in modulating
beta-catenin-independent Wnt-signaling has been suggested to mediate
its regulatory effect by binding and sequestering Sprouty. FZD receptor
Frizzled receptor; PAPC paraxial protocadherin; PKC Protein kinase C;
PLC phospholipase C; PTP1B protein tyrosine phosphatase 1B; RTK
receptor tyrosine kinase; TESK1 testicular protein kinase 1; CS
rearrangement cytoskeletal rearrangement. In this figure, C- and N-
terminus of the Sprouty molecule symbol are shown in white and blue,
respectively. Red lines indicate the Sprouty effect
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and regulators. Physiological functions of the Sprouty proteins
are cell-specific and context-dependent. As such, Sprouty
proteins are differentially induced in response to different
growth factors and elicit divergent cellular responses. More-
over, transcriptional and post-translational regulation of the
Sprouty content and activity provide spatiotemporal control of
the Sprouty-mediated regulation. As regards the implication in
malignancies, Sprouty has been the focus of research in a
variety of studies for the past decade. Different patterns of
the Sprouty deregulation have been reported in different can-
cers. As with normal cells, evidence shows that Sprouty in
malignancies functions in a cancer cell-specific and context-
dependent manner, hence its implication as a negative or
positive regulator of the tumor progression. The presence of
accompanying mutations of such oncogenes as RAS isoforms
has also been shown to be an important determinant of the
Sprouty’s deregulation and mode of action. To evaluate the
role of Sprouty in a particular cancer with respect to putative
clinical applications, in-depth investigation of the Sprouty’s
expression and mode of action in relation to the malignant
behavior of the cancer cell in the specific tumor microenvi-
ronment is warranted. This could give rise to a Sprouty-based
stratification of individual patients where it serves as a bio-
marker of prognosis or treatment sensitivity as well as a focus
of targeted strategies.
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